Cover
Vol. 3 No. 2 (2025)

Published: December 1, 2025

Pages: 122-131

Original Article

Evaluation The Laser Effects on Phage of Acentobacter Bumanii Isolated from Clinical Samples in Iraq/Qadisyiah

Abstract

Objective: Acinetobacter baumannii is a pathogenic bacterium with clinical attributes of nosocomial infection and resistance to antibiotics. Phage therapy represents a potential solution because it can specifically target MDR strains. This study aimed to isolate and characterize a lytic bacteriophage specific to A. baumannii, evaluate its kinetic and lytic properties, and investigate the effects of laser treatment on enhancing phage antibacterial activity against multidrug-resistant clinical isolates. Methods: Clinical specimens were collected from patients in three hospitals in Al-Diwaniyah, Iraq, and A. baumannii isolates were identified using standard biochemical tests, API systems, and 16S rRNA PCR sequencing. Environmental samples were screened to isolate lytic phages, which were propagated, purified, and analyzed using plaque assays and scanning electron microscopy. Phage kinetics—including adsorption rate, eclipse period, lysis time, and burst size—were assessed using standard bacteriophage quantification methods. Laser treatment was applied to evaluate its effect on phage activity under different temperatures and pH conditions. Results: A lytic phage specific to A. baumannii was successfully isolated, exhibiting an icosahedral head and a long tail typical of virulent phages. The phage showed rapid adsorption, a short eclipse period, and a high burst size (~111 phages per infected cell). It demonstrated strong lytic activity at temperatures between 35–45 °C and pH 8–10.5. Laser exposure, at 250 pulses, significantly enhanced phage antibacterial activity, resulting in faster bacterial lysis and increased phage productivity. Conclusions: The combination of phage therapy and laser treatment represents a promising strategy for combating MDR A. baumannii

References

  1. Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (Basel). 2020;9(3):119–35.
  2. Nocera FP, Attili AR, De Martino L. Acinetobacter baumannii: Its clinical significance in human and veterinary medicine. Pathogens. 2021;10(11):1270–85.
  3. Ahuatzin-Flores OE, Torres E, Chávez-Bravo E. Acinetobacter baumannii, a multidrug-resistant opportunistic pathogen in new habitats: A systematic review. Microorganisms. 2024;12(1):55–72.
  4. Chakravarty B. Genetic mechanisms of antibiotic resistance and virulence in Acinetobacter baumannii: Background, challenges and future prospects. Mol Biol Rep. 2020;47(8):6307–19.
  5. Zhao J, Zhu Y, Han J, Lin YW, Aichem M, Wang J, et al. Genome-scale metabolic modeling reveals metabolic alterations of multidrug-resistant Acinetobacter baumannii in a murine bloodstream infection model. Microorganisms. 2020;8(11):1793–1807.
  6. Martínez-Guitián M, Vázquez-Ucha JC, Álvarez-Fraga L, Conde-Pérez K, Vallejo JA, Perina A, et al. Global transcriptomic analysis during murine pneumonia infection reveals new virulence factors in Acinetobacter baumannii. J Infect Dis. 2021;223(8):1356–66.
  7. Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: A real challenge for clinicians. Antibiotics (Basel). 2020;9(4):205–20.
  8. Kisil OV, Efimenko TA, Gabrielyan NI, Efremenkova OV. Development of antimicrobial therapy methods to overcome the antibiotic resistance of Acinetobacter baumannii. Acta Naturae. 2020;12(3):34–43.
  9. Roy S, Chowdhury G, Mukhopadhyay AK, Dutta S, Basu S. Convergence of biofilm formation and antibiotic resistance in Acinetobacter baumannii infection. Front Med (Lausanne). 2022;9:793615.
  10. Shi J, Cheng J, Liu S, Zhu Y, et al. Acinetobacter baumannii: An evolving and cunning opponent. Front Microbiol. 2024;15:1298765.
  11. Grabowski Ł, Łepek K, Stasiłojć M, Kosznik-Kwaśnicka K, Zdrojewska K, Maciąg-Dorszyńska M, et al. Bacteriophage-encoded enzymes destroying bacterial cell membranes and walls and their potential use as antimicrobial agents. Microbiol Res. 2021;248:126746.
  12. Węgrzyn G. Should bacteriophages be classified as parasites or predators? Pol J Microbiol. 2022;71(2):161–7.
  13. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2006;12(7):1062–4.
  14. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
  15. Petrovic Fabijan A, Lin RC, Ho J, Maddocks S, Iredell JR, Lin AY. Safety of bacteriophage therapy in severe Clostridioides difficile infection. Nat Microbiol. 2020;5(3):465–72.
  16. Skaradzińska A, Olszewska-Tomczyk M, Łoś M, Lecion D, Węgrzyn G, Weber-Dąbrowska B. Bacteriophage therapy of Acinetobacter baumannii infections: The first steps to clinical trials. Future Microbiol. 2019;14(9):655–7.